- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2059-0105
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
mRNA vaccines induce rapid antibody responses in mice ; volume:7 ; number:1 ; day:1 ; month:8 ; year:2022 ; pages:1-7 ; date:12.2022
npj vaccines ; 7, Heft 1 (1.8.2022), 1-7, 12.2022
- Urheber
-
Gebre, Makda S.
Rauch, Susanne
Roth, Nicole
Gergen, Janina
Yu, Jingyou
Liu, Xiaowen
Cole, Andrew C.
Mueller, Stefan O.
Petsch, Benjamin
Barouch, Dan H.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41541-022-00511-y
- URN
-
urn:nbn:de:101:1-2022101820030700934194
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:29 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Gebre, Makda S.
- Rauch, Susanne
- Roth, Nicole
- Gergen, Janina
- Yu, Jingyou
- Liu, Xiaowen
- Cole, Andrew C.
- Mueller, Stefan O.
- Petsch, Benjamin
- Barouch, Dan H.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Impaired neutralizing antibody response to COVID-19 mRNA vaccines in cancer patients
Rapid development of double-hit mRNA antibody cocktail against orthopoxviruses
mRNA vaccines expressing malaria transmission-blocking antigens Pfs25 and Pfs230D1 induce a functional immune response
mRNA vaccines: A lucky shot?
Engineered Ferritin Nanoparticle Vaccines Enable Rapid Screening of Antibody Functionalization to Boost Immune Responses
Multivalent cytomegalovirus glycoprotein B nucleoside modified mRNA vaccines did not demonstrate a greater antibody breadth
mRNA vaccines in disease prevention and treatment
The advances of adjuvants in mRNA vaccines
Durable cross-protective neutralizing antibody responses elicited by lipid nanoparticle-formulated SARS-CoV-2 mRNA vaccines
Third primary SARS-CoV-2 mRNA vaccines enhance antibody responses in most patients with haematological malignancies
Self-amplifying mRNA seasonal influenza vaccines elicit mouse neutralizing antibody and cell-mediated immunity and protect ferrets
Advances in antibody-based HIV-1 vaccines development
Impaired neutralizing antibody response to COVID-19 mRNA vaccines in cancer patients
Rapid development of double-hit mRNA antibody cocktail against orthopoxviruses
mRNA vaccines expressing malaria transmission-blocking antigens Pfs25 and Pfs230D1 induce a functional immune response
mRNA vaccines: A lucky shot?
Engineered Ferritin Nanoparticle Vaccines Enable Rapid Screening of Antibody Functionalization to Boost Immune Responses
Multivalent cytomegalovirus glycoprotein B nucleoside modified mRNA vaccines did not demonstrate a greater antibody breadth
mRNA vaccines in disease prevention and treatment
The advances of adjuvants in mRNA vaccines
Durable cross-protective neutralizing antibody responses elicited by lipid nanoparticle-formulated SARS-CoV-2 mRNA vaccines
Third primary SARS-CoV-2 mRNA vaccines enhance antibody responses in most patients with haematological malignancies
Self-amplifying mRNA seasonal influenza vaccines elicit mouse neutralizing antibody and cell-mediated immunity and protect ferrets
Advances in antibody-based HIV-1 vaccines development
Impaired neutralizing antibody response to COVID-19 mRNA vaccines in cancer patients
Rapid development of double-hit mRNA antibody cocktail against orthopoxviruses
mRNA vaccines expressing malaria transmission-blocking antigens Pfs25 and Pfs230D1 induce a functional immune response
mRNA vaccines: A lucky shot?
Engineered Ferritin Nanoparticle Vaccines Enable Rapid Screening of Antibody Functionalization to Boost Immune Responses
Multivalent cytomegalovirus glycoprotein B nucleoside modified mRNA vaccines did not demonstrate a greater antibody breadth
mRNA vaccines in disease prevention and treatment
The advances of adjuvants in mRNA vaccines
Durable cross-protective neutralizing antibody responses elicited by lipid nanoparticle-formulated SARS-CoV-2 mRNA vaccines
Third primary SARS-CoV-2 mRNA vaccines enhance antibody responses in most patients with haematological malignancies
Self-amplifying mRNA seasonal influenza vaccines elicit mouse neutralizing antibody and cell-mediated immunity and protect ferrets